-
Mashup Score: 0Baricitinib Has Reinvigorated Patients with Alopecia Areata - 2 year(s) ago
Brett King, MD, PhD, discusses the newly available JAK inhibitor—the first systemic therapy approved for the hair-loss condition.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 2Baricitinib in the Treatment of COVID-19 - 2 year(s) ago
Baricitinib is a novel Janus kinase (JAK) inhibitor which has recently been included in recommendations for treatment of COVID-19. This chapter is focused on discussing the evidence available regarding the safety and efficacy of use of baricitinib alone or in combination with other therapies for treatment of patients with COVID-19. A systematic literature search was conducted for this purpose to…
Source: www.intechopen.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
Comprehensive full-read review of #Baricitinib trials in treating COVID-19. 24 studies (16 retrospective, 5 prospective, 3 case control) studies & 3 larged RCTs show Bari as 24-38% better than comparators/SOC (few showed no change in mortality) https://t.co/2svMMX4wDw https://t.co/zoSGGZJYui
-
-
Mashup Score: 3Baricitinib in the Treatment of COVID-19 - 2 year(s) ago
Baricitinib is a novel Janus kinase (JAK) inhibitor which has recently been included in recommendations for treatment of COVID-19. This chapter is focused on discussing the evidence available regarding the safety and efficacy of use of baricitinib alone or in combination with other therapies for treatment of patients with COVID-19. A systematic literature search was conducted for this purpose to…
Source: www.intechopen.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
Comprehensive full-read review of #Baricitinib trials in treating COVID-19. 24 studies (16 retrospective, 5 prospective, 3 case control) studies & 3 larged RCTs show Bari as 24-38% better than comparators/SOC (few showed no change in mortality) https://t.co/pps1Du9rEt https://t.co/ZEDiHwZ5po
-
-
Mashup Score: 4NEJM Journal Watch: Summaries of and commentary on original medical and scientific articles from key medical journals - 2 year(s) ago
NEJM Journal Watch reviews over 250 scientific and medical journals to present important clinical research findings and insightful commentary
Source: www.jwatch.orgCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
In the RECOVERY trial, adding #baricitinib to dexamethasone reduced mortality in hospitalized patients with #COVID19. https://t.co/WBvgrDckbc @RMKGandhi https://t.co/mtRaArQpGy
-
-
Mashup Score: 3
The study, which assessed data from the JUVE-BASIS trial, suggests baricitinib significantly reduced both the time to and frequency of flares in patients with JIA when compared with placebo.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
Results from a University of Bristol-led analysis of a phase 3 trial are providing clinicians with insight into use of #baricitinib in the management of juvenile idiopathic #arthritis. https://t.co/sv6tgl8XmL
-
-
Mashup Score: 0
Several prominent dermatologists sound off on the implications of this decision, JAK inhibitors, and how this approval will aid providers in redefining alopecia areata as an autoimmune disorder rather than simply a cosmetic condition.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
Dr. Brett King (@YaleMed , @yalederm ) talks of treating severe #AlopeciaAreata with #Baricitinib , the first systemic treatment approved by the #FDA for the disorder. #dermtwitter Hear from Dr. King and more in the new #DocTalk episode: https://t.co/X9w7WgxiWD https://t.co/IVw6zIy0b4
-
-
Mashup Score: 0
Several prominent dermatologists sound off on the implications of this decision, JAK inhibitors, and how this approval will aid providers in redefining alopecia areata as an autoimmune disorder rather than simply a cosmetic condition.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
The new #DocTalk is here! Dermatologists discuss the #FDA approval of #baricitinib for #alopeciaareata. Featuring @YaleMedicine 's Dr. Brett King and Dr.Britt Craiglow, Dr. Lisa Arkin (@UWMedicine ), and Dr. Karan Lal (@SocietyPedsDerm ) https://t.co/VTUbMfG23s
-
-
Mashup Score: 1
The study, which assessed data from the JUVE-BASIS trial, suggests baricitinib significantly reduced both the time to and frequency of flares in patients with JIA when compared with placebo.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
The study, which assessed data from the JUVE-BASIS trial, suggests #baricitinib significantly reduced both the time to and frequency of flares in patients with #JIA when compared with placebo. https://t.co/owg9fqSrKk #EULAR2022
-
-
Mashup Score: 1Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus - 2 year(s) ago
Objectives To elucidate the mechanism of action of baricitinib, a Janus kinase (JAK) 1/2 inhibitor, and describe immunological pathways related to disease activity in adults with systemic lupus erythematosus (SLE) receiving standard background therapy in a phase II trial. Methods Patients with SLE were treated with baricitinib 2 mg or 4 mg in a phase II randomised, placebo-controlled study. Sera…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
Which are the (immuno)mechanisms of action of #baricitinib in #lupus? ▶️ strong decrease in a number of cytokines, including CCL19, CXCL-10, TNF-α, TNFRSF9/CD137, PD-L1, IL-6 and IL-12β ▶️ some correlated with IFN signature, and to disease activity 🔗 https://t.co/Ol0bcbVseA https://t.co/8DNL6Xxhw4
-
-
Mashup Score: 7Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial - 2 year(s) ago
In hospitalised patients with COVID-19 requiring supplemental oxygen by low-flow, high-flow, or non-invasive ventilation, baricitinib plus remdesivir and dexamethasone plus remdesivir resulted in similar mechanical ventilation-free survival by day 29, but dexamethasone was associated with significantly more adverse events, treatment-related adverse events, and severe or life-threatening adverse…
Source: The Lancet Respiratory MedicineCategories: Critical Care, Latest HeadlinesTweet-
💥 Hot: #Baricitinib as good as steroids & causes ⬇️ severe adverse events in hospitalized #COVID pts on O2. 5th Major Study. >12,000 pts now. N=1,010 pts in 67 sites solidifies newly FDA-approved anti-inflammatory med as safe, top-tier COVID drug. https://t.co/oMoizvsLWh https://t.co/EjurGwl5e2
-
“We’ve finally landed at the goal, and the future is bright now." @Brett_King_ discusses the introduction of #baricitinib to the alopecia market: a historic indication years in the making. From #FallClinical22: https://t.co/UNvPSMZbss